{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(3)"],"submitter":["Rousseau JF"],"pubmed_abstract":["<h4>Importance</h4>Tenecteplase is an alternative to alteplase for emergency treatment of acute ischemic stroke. However, limited data are available comparing their clinical effectiveness in routine clinical practice.<h4>Objective</h4>To compare short-term effectiveness and safety outcomes for patients with ischemic stroke treated with intravenous tenecteplase vs alteplase.<h4>Design, setting, and participants</h4>This comparative effectiveness study used data prospectively collected from July 1, 2020, through June 30, 2022, from the Get With The Guidelines-Stroke registry.<h4>Exposure</h4>Consecutive patients with ischemic stroke treated with either tenecteplase or alteplase within 4.5 hours from last known well time were included.<h4>Main outcomes and measures</h4>The primary end point w"],"journal":["JAMA network open"],"pagination":["e250548"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11904722"],"repository":["biostudies-literature"],"pubmed_title":["Short-Term Safety and Effectiveness for Tenecteplase and Alteplase in Acute Ischemic Stroke."],"pmcid":["PMC11904722"],"pubmed_authors":["Rousseau JF","Messe SR","Schwamm LH","Fonarow GC","Xian Y","Sheth KN","Silva GS","Alhanti B","Saver JL","Mac Grory B","Smith EE","Weber JM","Warach SJ","Mullen MT"],"additional_accession":[]},"is_claimable":false,"name":"Short-Term Safety and Effectiveness for Tenecteplase and Alteplase in Acute Ischemic Stroke.","description":"<h4>Importance</h4>Tenecteplase is an alternative to alteplase for emergency treatment of acute ischemic stroke. However, limited data are available comparing their clinical effectiveness in routine clinical practice.<h4>Objective</h4>To compare short-term effectiveness and safety outcomes for patients with ischemic stroke treated with intravenous tenecteplase vs alteplase.<h4>Design, setting, and participants</h4>This comparative effectiveness study used data prospectively collected from July 1, 2020, through June 30, 2022, from the Get With The Guidelines-Stroke registry.<h4>Exposure</h4>Consecutive patients with ischemic stroke treated with either tenecteplase or alteplase within 4.5 hours from last known well time were included.<h4>Main outcomes and measures</h4>The primary end point w","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Mar","modification":"2026-06-06T23:41:34.747Z","creation":"2025-04-22T07:25:23.806Z"},"accession":"S-EPMC11904722","cross_references":{"pubmed":["40072434"],"doi":["10.1001/jamanetworkopen.2025.0548"]}}